Experience

10/2022 – Still: İstanbul Oncology Hospital  

Medical Oncologist

01/2021 – 10/2022: Gaziantep Dr. Ersin Arslan Research and Training Hospital

Medical Oncologist

10/2017 – 12/2020: İstanbul Medeniyet University Hospital  

Medical Oncology Fellow

10/2016 – 09/2017: Mardin Public Hospital  

Internal Medicine Specialist

08/2012– 09/2016: İstanbul Research and Training Hospital

Internal Medicine Resident

11/2006– 07/2010: Antalya Hava Meydan Komutanlığı

General practitioner

Education  

Oncology Fellowship:  İstanbul Medeniyet University

                                 Medical Oncology   10/2017 – 10/2020  

Internal Medicine Residency: İstanbul Research and Training Hospital

                                 Internal Medicine  08/2012– 09/2016

School of Medicine: Gülhane Faculty of Medicine

                                  School of Medicine   09/2000 – 11/2006  

Experience and Certificate

12/2019-03/2020  Moffitt Cancer Center (Tampa/FLORIDA)

ESMO Board Certified – 2019

Turkish Society of Medical Oncology

ASCO(American Society of Clinical Oncology)  

ESMO(European Society of Medical Oncology)  

Turkish Society of Internal Medicine  

English

German 

Okten IN, Ismail S, Withycombe BM, Eroglu Z. Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.Expert Opin Drug Discov. 2020 Dec;15(12):1373-1380. doi: 10.1080/17460441.2020.1795124. Epub 2020 Jul 28.

Yildiz B, Kucukarda A, Gokyer A, Gokcen Demiray A, Paydas S, Pinar Aral I, Gumusay O, Bilici A, Akdeniz N, Bahceci A, Demir H, Esin E, Üyeturk U, Nihat Okten I, Erturk I, Turk HM, Topaloglu US, Basoglu T, Serdar Turhal N, Yesil Cinkir H, Menekse S, Cakmak Y, Urun Y, Acar R, Kut E, Dal P, Sakalar T, Halit Aktepe O, Karadurmus N, Bilici A. Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.J BUON. 2020 Mar-Apr;25(2):1130-1135.

Telli TA, Okten IN, Tuylu TB, Demircan NC, Arikan R, Alan O, Ercelep O, Ones T, Yildirim AT, Dane F, Yumuk PF. VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: A case series with review of the literature. Curr Probl Cancer. 2020 Oct;44(5):100568. doi: 10.1016/j.currproblcancer.2020.100568. Epub 2020 Mar 14.

Cil I, Kucukarda A, Atcı MM, Secmeler S, Paksoy N, Ferhatoglu F, Ak N, Ayhan M, Tataroglu Ozyukseler D, Onder AH, Avci O, Oyman A, Okten IN, Gulturk I, Akagunduz B, Basoglu T, Cakir E, Hacibekiroglu I, Ozcelik M, Aydiner A. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739. Epub 2021 Aug 7.

Atmaca, H. U., Akbaş, F., Ökten, İ. N., Nuhoğlu, E., & İnal, B. B. (2014). Can neutrophil-to-lymphocyte ratio serve as an inflammatory marker in obesity?. renal failure, 10, 15.

Oyman, A., Ibrahim, C. İ. L., Özçelik, M., Özyükseler, D. T., Başak, M., Gökyer, A., & Ökten, İ. N. (2022). Evaluation of LIPI and mGPS as prognostic factors in extensive-stage small-cell lung cancer. Journal of Surgery and Medicine, 6(2), 115-119.

Alan, O., Akin Telli, T., Aktas, B., Koca, S., Ökten, I. N., Hasanov, R., ... & Yumuk, P. F. (2020). Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?. World Journal of Surgical Oncology, 18(1), 1-9.

Isik, Ulas, et al. "Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer." (2019): e16075-e16075.

Okten, I. N., Aktas Sezen, B., Gunaydin, U. M., Koca, S., Ozturk, T., Ozder, H. T., & Gumus, M. (2018). Factors associated with delayed diagnosis and treatment in patients with cancer.

Gumus, Mahmut, et al. "Neoadjuvant treatment in patients with locally advanced gastric cancer." (2019): 127-127.

ÖVEN, Bala Başak, et al. "Benefits of Neoadjuvant Chemotherapy for Luminal Breast Cancer with Respect to Tumor Response." Journal of oncological sciences 7.1 (2021): 7-14.

Yıldız, B., Küçükarda, A., Gökyer, A., Demiray, A. G., Paydaş, S., Aral, İ. P., ... & Karadurmuş, N. (2020). Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.

ÇİL, İ., OYMAN, A., IŞIK, S., AYHAN, M., ÖKTEN, İ. N., YILMAZ, M., & ÖZÇELİK, M. (2021). Prognostic Factors in Resected Biliary Tract Cancers and the Impact of Cytokeratin 20 Expression. Journal of oncological sciences, 7(3), 125-132.

Canan, E. R. E. N., Ayten GÜNER AKBIYIK, and İlker Nihat ÖKTEN. "Analysis of The Relationship between Blood Groups and Lung Cancer Risk Depending on Histology." Düzce Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi 11.3: 386-390.

Sinan Koca , Esra Koca , Ilker N Okten , Fatma Fc Orengül , Akın Oztürk , Melike Ozçelik , Abdilkerim Oyman , Ibrahim Çil, Mahmut Gümüş Psychological impacts of COVID-19 pandemic in cancer patients on active treatment. 2022 Aug;8(8):e10142. doi: 10.1016/j.heliyon.2022.e10142. Epub 2022 Aug 18.

Akagunduz, Baran AU  - Guven, Deniz Can AU  - Ozer, Muhammed AU  - Okten, İlker Nihat AU  - Atag, Elif AU  - Unek, İlkay AU  - Tatli, Ali AU  - Karaoglu, Aziz PY  - 2022/08/01 SP  -  T1  - Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer DO  - 10.1016/j.jgo.2022.08.016 JO  - Journal of Geriatric Oncology ER  -

Clinical Trial Experience

ARandomized,Double-Blind,PhaseIIIPlaceboControlledTrialofPemrolizumab (MK3475) in Combination with Cisplatin with and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination Advanced/Metastatic Esophagel Carcinoma –Sub Investiagor

A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab- Paclitaxel Chemoterapy with or without Pembrolizumab (MK3475) in First Line Metastatic Squamous Non-Small Cell Lung Cancer Subjects – Sub Investigator

A Phase 3 Randomized, Double Blind, Placebo Controlled Trial of Pemrolizumab (MK3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subject with Extensive Stage Small Lung Cancer – Sub Investigator

A Randomized,Open-Label,Phase3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer - Sub Investigator

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docataxel or Pembrolizumab in Subjects with Advanced Urethelial Cancer and Selected EGFR Gene Aberrations- Sub Investigator

A Multicenter, Randomized, Open–label, 3-Arm Phase 3 Study of Encorafenib+Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or 5-Fluorouracil (5FU)/Folinic Acid (FA) / Irinotecan (FOLFIRI) /Cetuximab with a Safety Lead-in of Encorafenib+ Binimetinib+ Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer – Sub Investigator

A phase III, Multcenter, Randomısed, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Antı−Pd-L1 Antibody) In Combinatıon With Paclitaxel Compared With Placebo With Paclitaxel For Patients With Previously Untreated Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer – Sub Investigator

A Multicenter, Randomized, Double-blind, Phase III Study of BAT1706 versus EU- Avastin® plus Chemotherapy in Patients with Advanced Non-squamous Non-Small Cell Lung Cancer-Sub Investigator

A Global, Randomized, Phase 3, Open-Label Study Of Regn2810(Anti-Pd-1 Antibody) Versus Platinum- Based Chemotherapy In First-Line Treatment Of Patients With Advanced Or Metastatic Pd-L1 + Non-Small Cell Lung Cancer-

A randomized, double blind, placebo-controlled multi-center study to assess the efficacy and safety of AZD9291 versus placebo, in patients with epidermal growth factor receptor mutation positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemoterapy, phase III- Sub Investigator

A Randomized, Double Blind, Placebo – Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum- Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU) - Sub Investigator

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel- Group Study of B-701 Plus Docetaksel Versus Placebo in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carsinoma in Subjects who have Relapsed After, or are Refractory to Standard Therapy - Sub Investigator

A Randomized, Phase 3 Trial With Anti-PD Monoclonal Antibody Pembrolizumab (MK3475) Versus Placebo For Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)- Sub Investigator

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966)- Sub Investigator

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)- Sub Investigator

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)- - Sub Investigator

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight) - Sub Investigator

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)